Pfizer (PFE) Current Deferred Tax Assets (2010 - 2026)

Pfizer (PFE) has 17 years of Current Deferred Tax Assets data on file, last reported at $3.6 billion in Q1 2026.

• Current Deferred Tax Assets for Q1 2026 came in at $3.6 billion, up 23.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 billion (up 23.72% YoY), and the FY2025 annual result was $4.0 billion, up 19.7% from the prior year.
• Current Deferred Tax Assets eased to $3.6 billion in Q1 2026 per PFE's latest filing, from $4.0 billion in the prior quarter.
• Over five years, Current Deferred Tax Assets peaked at $4.2 billion in Q1 2024 and troughed at $2.5 billion in Q4 2022.
• A 5-year average of $3.5 billion and a median of $3.6 billion in 2022 frame the typical range for Current Deferred Tax Assets.
• The sharpest annual moves came in 2022 and 2023: Current Deferred Tax Assets tumbled 34.38% in 2022, then soared 53.97% in 2023.
• A 5-year view of Current Deferred Tax Assets shows it stood at $3.6 billion in 2022, then grew by 11.21% to $4.0 billion in 2023, then declined by 16.69% to $3.3 billion in 2024, then advanced by 19.7% to $4.0 billion in 2025, then dropped by 9.55% to $3.6 billion in 2026.
• Business Quant data shows PFE's Current Deferred Tax Assets at $3.6 billion in Q1 2026, $4.0 billion in Q4 2025, and $3.9 billion in Q3 2025.